New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Review Oncology

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Mihaela Aldea et al.

Summary: Resistance to anticancer therapies can be classified into primary and secondary resistance, primarily influenced by target dependency and cellular adaptability. Immunotherapy resistance is often driven by tumor-host-microenvironment interactions, while targeted therapy resistance is typically driven by alterations in targets.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Kanwal Raghav et al.

Summary: The AtezoBev combination therapy showed promising and durable efficacy in patients with advanced MPeM, addressing a significant unmet need for this rare disease. Biomarker analyses highlighted epithelial-mesenchymal transition phenotype as a key resistance mechanism, demonstrating the value of translational clinical trials in rare tumors.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Prasad S. Adusumilli et al.

Summary: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is safe, feasible, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Medicine, General & Internal